Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Corvus Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 47 | 1 | 62 | +16 |
| Shares | 27.6M | 562.0K | 30.0M | +3.00M (+11.1%) |
| Value | $50.2M | $1.02M | $158.5M | +$109.3M (+222.3%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vivo Capital, LLC | 1,497,268 | $7.91M | 0.65% |
| BlackRock, Inc. | 603,877 | $3.19M | 0.00% |
| Ghost Tree Capital, LLC | 500,000 | $2.64M | 0.90% |
| Goldman Sachs Group Inc | 376,121 | $1.99M | 0.00% |
| Schonfeld Strategic Advisors LLC | 331,360 | $1.75M | 0.01% |
| Qube Research & Technologies Ltd | 127,332 | $672.3K | 0.00% |
| Citigroup Inc | 122,858 | $648.7K | 0.00% |
| Acadian Asset Management LLC | 79,735 | $420.0K | 0.00% |
| Jane Street Group, LLC | 50,221 | $265.2K | 0.00% |
| Mission Wealth Management, LP | 40,000 | $211.2K | 0.01% |
| Ancora Advisors, LLC | 23,285 | $122.9K | 0.00% |
| Oppenheimer & Co Inc | 16,947 | $89.5K | 0.00% |
| Virtu Financial LLC | 15,694 | $83.0K | 0.00% |
| XTX Topco Ltd | 14,086 | $74.4K | 0.01% |
| Squarepoint Ops LLC | 12,080 | $63.8K | 0.00% |
| Nwam LLC | 10,050 | $53.1K | 0.00% |
| Group One Trading, L.P. | 5,560 | $29.4K | 0.00% |
| BNP Paribas Arbitrage, SA | 3,110 | $16.4K | 0.00% |
| Western Pacific Wealth Management, LP | 2,000 | $10.6K | 0.01% |
Sold out (3)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 15,300 | $27.8K |
| Two Sigma Securities, LLC | 11,384 | $20.7K |
| Royal Bank of Canada | 7,238 | $13.0K |
Not filed for Q3 2024 yet (1)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 562,024 | $1.02M |